| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/ERI.11.133 |
| P698 | PubMed publication ID | 22114960 |
| P2093 | author name string | Andrew J Muir | |
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| Coinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical Outcomes | Q27488883 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus | Q28279955 | ||
| Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose | Q29547886 | ||
| Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
| Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium | Q29619747 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Telaprevir for previously treated chronic HCV infection | Q34109057 | ||
| Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection | Q34607097 | ||
| Response-guided telaprevir combination treatment for hepatitis C virus infection | Q34632295 | ||
| IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C | Q35838595 | ||
| Treatment of hepatitis C virus reinfection after liver transplantation | Q36312694 | ||
| Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy | Q37726075 | ||
| ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. | Q39920642 | ||
| Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function | Q39965118 | ||
| Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients | Q42978510 | ||
| Telaprevir and peginterferon with or without ribavirin for chronic HCV infection | Q42987218 | ||
| Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 | ||
| Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study | Q43032179 | ||
| A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. | Q43035164 | ||
| Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir | Q43037585 | ||
| Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients | Q43039768 | ||
| Changing trends in hepatitis C-related mortality in the United States, 1995-2004. | Q46370317 | ||
| Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. | Q50557485 | ||
| P433 | issue | 12 | |
| P921 | main subject | chronic hepatitis C | Q55779873 |
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 1105-1114 | |
| P577 | publication date | 2011-12-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Telaprevir for the treatment of chronic hepatitis C infection | |
| P478 | volume | 9 |
Search more.